Entera Bio Ltd. (NASDAQ:ENTX) is expected to report second quarter earnings results, before market open, on Thursday 20th August 2020.
Previous Quarter Performance
Entera Bio Ltd. posted loss for the first quarter of $ 0.16 per share, from the revenue of $ 0.04 million. The quarterly earnings decreased 44.52 percent compared with the same quarter last year. Wall street analysts are predicting revenue of The bottom line results street analysts by $ 0.13 or , at the same time, top line results analysts by $ 299.07 million or .
Stock Performance
According to the previous trading day, closing price of ENTX was $ 1.40, representing a 0.72 % increase from the 52 week low of $ 1.39 and a 58.82 % decrease over the 52 week high of $ 3.40.
The company has a market capital of $ 25.53 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Entera Bio Ltd. will be hosting a conference call at 8:30 AM eastern time on 20th August 2020, to discuss its 2Q20 financial results with the investment community. The participants may dial, (855) 547-3865 U.S. or (409) 217-8787 Toll Number, when prompted, enter passcode 5243229 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website edge.media-server.com/mmc/p/zbs5xewg
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The companys lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules.
